Pharmacological Advances in Central Nervous System Stimulants

Pharmacological Advances in Central Nervous System Stimulants, Volume 99 in the Mechanisms, Therapeutic Uses, and Abuse of Stimulants series, showcases recent pharmacological progress investigating both therapeutic (ADHD, binge-eating and narcolepsy) and abuse aspects of a number of stimulants, some of which are long-standing (amphetamines, cocaine and nicotine) while others are emerging (cathinones). Specific chapters in this new release include Transgenerational Epigenetic Inheritance of Phenotypes Associated with Parental Exposure to Drugs of Abuse, Dysregulation Of Brain Cholesterol Homeostasis by Psychostimulants, Modeling Methamphetamine Use Disorder in Mammals: Sex Differences in Behavioral Consequences and Gene Expression, and much more.Additional sections focus on Second Generation Stimulants – Pharmacological and Clinical Advances in The Treatment of ADHD And Binge-eating disorder, Pharmacology Of Stimulant – Opioid Co-Use, Role Of Age and Sex in Determining the Risk For Adverse Consequences Following Exposure To Amphetamines, Modafinil, An Atypical CNS Stimulant, Modulators Of Nicotine Reward-Related and Reinforcement-Related Behaviors, Methamphetamine Effects on Peripheral Immune System, Post-Translational Mechanisms in Neurotransmitter Efflux, The Many Enigmas of Nicotine, Genetic Variation in The Neuregulin-Erbb Signaling Pathway And Substance Use Disorders, Pharmacology And Neurotoxicology of Synthetic Cathinones, and more.- Provides a diverse variety of stimulants, having different mechanisms of action and physiological effects- Includes both therapeutic uses and abuse aspects of stimulants- Covers both molecular mechanisms and behavioral effects of stimulants

About the Author

Margaret E. Gnegy is a Professor Emerita (active) in the Department of Pharmacology at The University of Michigan. She received her Ph.D. in Biochemistry in 1975 from West Virginia University. She conducted her post-doctoral studies in the Laboratory of Preclinical Pharmacology at the National Institutes of Mental Health under the tutelage of Dr. Erminio Costa. Her research interests focused on signal transduction mechanisms, particularly protein kinase C, that regulate the action of amphetamine at the dopamine transporter and how they affect reinforcement. In the past few years, her laboratory designed and tested CNS-permeant drugs (PKCβ inhibitors) for inhibition of amphetamine-stimulated dopamine release and amphetamine-stimulated behaviors that assess motivation for drug seeking and taking. For three years Dr. Gnegy served as the Director of the UM Substance Abuse Research Center and for 8 years was the Principle Investigator on the T32 Substance Abuse Interdisciplinary Training Program funded by the National Institutes of Drug Abuse. She also serves as Chair of the Pharmacology Graduate Program for over 20 years. Nineteen pre-doctoral students and 12 post-doctoral fellows have been trained in her laboratory and she has served as mentor to young UM faculty within and outside of the Pharmacology Department. In recognition of her exemplary performance in mentoring and training, the UM conferred upon Dr. Gnegy the Rackham Distinguished Graduate Mentor Award for 2009. She has served as President of both the American Association for Pharmacology and Experimental Therapeutics (ASPET) and the Catecholamine Society. Dr. Gnegy also served as an Associate Editor of the journal Pharmacology & Therapeutics. In 2019 she was named an AAAS Fellow.